Ben Venue Consent Decree Could Be Signal on Hospira, Analyst Says

Drug GMP Report
A A
Boehringer Ingelheim subsidiary Ben Venue Laboratories has signed a consent decree to resolve a history of GMP slipups.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00